Navigation Links
MEK162 Registration Path Announced
Date:11/8/2012

BOULDER, Colo., Nov. 8, 2012 /PRNewswire/ -- At its R&D Investor event earlier today, Novartis provided an update on the clinical development strategy for MEK162 (ARRY-162).  Novartis intends to initiate pivotal trials in patients with NRAS mutant melanoma during 2013, with the goal of regulatory submissions on or after 2016.  In addition, Novartis announced plans to pursue clinical development in combination with a Raf inhibitor, in BRAF mutant melanoma, with regulatory submissions forecast for on or after 2016.  To listen to the webcast or view the slides from the R&D Investor event, please click here:  http://www.novartis.com/investors/event-calendar/index.shtml#2012-11-08_investor

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

"We are pleased that Novartis is expected to advance MEK162 into pivotal trials next year," said Ron Squarer, Chief Executive Officer, Array BioPharma.  "Based on the positive Phase 2 trial results in NRAS mutant melanoma, MEK162 may provide a new option for patients with particularly poor prognoses.  We are also excited that Novartis is building on their positive trial results in patients with BRAF melanoma to pursue an additional clinical program in this population."

Array BioPharma Inc. (NASDAQ: ARRY) invented MEK162 and licensed worldwide rights to develop and commercialize MEK162 to Novartis in April 2010.  As part of the agreement, Array is co-developing MEK162 with Novartis and retains an option to co-detail the product in the US.

MEK162 Phase 2 BRAF/NRAS Phase 2 Trial Results
The ongoing Phase 2 open-label trial with MEK162 as a single agent is being conducted by Novartis and continues to enroll patients.  As reported at ASCO, the disease control rate (partial r
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pennsylvania DEP Announces X-ray Registration Fee Amnesty Program
2. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
3. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
4. PatientPay from Zepherella Makes Patient Registration and Payment Pre-Authorization Faster, Easier for Physician Groups
5. Last Chance to Save on Boston-Area Mobile Health, Biotech, and Pharmaceutical Conference Registration
6. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
7. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. Gen-Probe Withdraws from Previously Announced Investor Presentations
9. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
10. LTCLINK-Tank Competition Announced To Introduce Your Emerging Product to the Aging Care Continuum
11. Delcath Announced Changes To Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... Dec. 23, 2014 PuraMed BioScience®, Inc., (OTC ... (OTC) medicinal and healthcare products, announced it received the ... a hemp-based, advanced headache relief product, for planned distribution ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel formulation ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical Isotope ... engaged primarily in the development of brachytherapy devices ... today announced that it has filed a ... Drug Administration ("FDA") for marketing clearance for its ... of the U.S. Food, Drug and Cosmetic Act ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Aug. 22, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... launch and availability of ONSOLIS (fentanyl buccal soluble film) ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ONSOLIS is approved in ... be marketed as BREAKYL) for the management of breakthrough ...
... the Food and Drug Administration (FDA) approved Seattle Genetics, ... – Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). ... approved for Hodgkin lymphoma patients after failure of a ... ALCL patients after failure of at least one multi-agent ...
Cached Medicine Technology:BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 2BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 3The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics' Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977 2
(Date:12/24/2014)... (PRWEB) December 24, 2014 New studies reveal ... to hearing loss related depression (March 6, 2014, JAMA Otolaryngology*). ... gradual hearing loss (about 50 percent according to recent polls) ... effect on how a person feels and relates to the ... overall improvements are also made by way of:, ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
(Date:12/24/2014)... News) -- Hepatitis C infection does not contribute to mental ... Treatment advances have made it possible for people with ... thinking problems, mood swings and other types of mental impairment ... that long-term infections with other viruses -- a common problem ... of the prime suspects has been the hepatitis C virus, ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A lab technician with ... have been exposed to the Ebola virus in an ... up to a dozen other lab workers are being ... afternoon. The possible exposure occurred Monday when CDC ... of the potentially lethal virus to another CDC lab ...
(Date:12/24/2014)... Dr. Svetlana Gomer, MGS Tewksbury Dental, MGE Management ... US Marines on November 14, 2014 for the MGE ... for Tots Literacy Program. This year’s event raised ... audio books for the Toys for Tots Literacy Program ... represents another major strike in the battle being waged ...
Breaking Medicine News(10 mins):Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... Researchers at the University of Toronto have identified a ... of neurons, which could enhance our understanding of how ... occur. U of T graduate student John Calarco, ... Centre for Cellular and Biomolecular Research, University of Toronto) ...
... mild depression more likely to suffer major episode later, ... Mildly depressed teenagers are more likely to have major ... new study suggests. , In 1983, researchers interviewed 755 ... and eating disorders, disruptive behaviors and substance abuse. , ...
... ... get Vaccinated , ... Washington, DC (Vocus) - The American Pharmacists Association (APhA) is recommending that ... vaccinated against influenza. Currently almost 80,000 pharmacists have been trained to administer immunizations and ...
... , , MINNEAPOLIS, Sept. ... at all 22 Target Clinic locations in Minnesota. The Centers ... against this potentially serious illness. , , ... available daily at Target Clinic locations during Clinic hours, including ...
... - Hard to Treat Diseases (the "Company") (HTDS.PK) ... Hope, has just finished (August 2009) the clinical ... NUTRIPROTEIN) in India. , This biological product is ... CNS in multiple ways, regulating and improving nerve ...
... could do the same, researchers say , FRIDAY, Sept. 4 ... animals may have a mechanism that allows them to jettison ... any age can do the same. , In fact, scientists ... go into deep storage. , "It,s fair to say that ...
Cached Medicine News:Health News:U of T researchers identify protein 2Health News:Depressed Teens Continue to Suffer 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 3Health News:Seasonal Flu Vaccinations Available Now at Target Clinics in Minnesota 2Health News:Seasonal Flu Vaccinations Available Now at Target Clinics in Minnesota 3Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 2Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 3Health News:Young Animals May Be Able to Erase Bad Memories 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: